Increasing feasibility and utility of 18F-FDOPA PET for the management of glioma by Bell, Christopher et al.
  	

Increasing feasibility and utility of 18F-FDOPA PET for the management of
glioma
Christopher Bell, Nicholas Dowson, Simon Puttick, Yaniv Gal, Paul
Thomas, Mike Fay, Jye Smith, Stephen Rose
PII: S0969-8051(15)00093-1
DOI: doi: 10.1016/j.nucmedbio.2015.06.001
Reference: NMB 7732
To appear in: Nuclear Medicine and Biology
Received date: 23 February 2015
Revised date: 27 May 2015
Accepted date: 3 June 2015
Please cite this article as: Bell Christopher, Dowson Nicholas, Puttick Simon, Gal Yaniv,
Thomas Paul, Fay Mike, Smith Jye, Rose Stephen, Increasing feasibility and utility of
18F-FDOPA PET for the management of glioma, Nuclear Medicine and Biology (2015),
doi: 10.1016/j.nucmedbio.2015.06.001
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Increasing feasibility and utility of 18F-FDOPA PET for the management of 
glioma 
Christopher Bella,b, Nicholas Dowsona, Simon Puttickc, Yaniv Gald, Paul 
Thomase, Mike Fayb,f,g, Jye Smithb,g, Stephen Rosea,* 
a CSIRO Preventative Health Flagship, CSIRO Computational Informatics, 
The Australian e-Health Research Centre, Herston QLD 4029, Australia  
b The University of Queensland, School of Medicine, St Lucia, QLD 4072, 
Australia 
c Australian Institute for Bioengineering and Nanotechnology, The University 
of Queensland, St Lucia, QLD 4072, Australia 
d The University of Queensland, Centre for Medical Diagnostic Technologies 
in Queensland, St Lucia, QLD 4072, Australia 
e Department of Radiation Oncology, Royal Brisbane and Women's Hospital, 
Herston, QLD 4029, Australia 
f Genesis Cancer Care, Lake Macquarie Private Hospital, 36 Pacific Highway, 
Gateshead, NSW 2290, Australia 
g Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, 
Herston, QLD 4029, Australia 
Correspondence: 
Assoc Prof Stephen Rose 
CSIRO Computational Informatics 
Royal Brisbane and Women’s Hospital,  
Brisbane 4029 Australia 
Stephen.Rose@csiro.au 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Telephone +61 7 32533620 
 
Word count: ??? (Abstract), ??? (Text, Table and Figures) ???; 1 figures, 1 
table  
Keywords:  Glioblastoma, infiltration, PET, 18F-FDOPA, glioma, dopamine 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Abstract 
Introduction 
Despite radical treatment therapies, glioma continues to carry with it a 
uniformly poor prognosis. Patients diagnosed with WHO grade IV glioma 
(glioblastomas; GBM) generally succumb within two years, even those with WHO 
Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 
years, respectively. PET imaging with 18F-FDOPA allows in vivo assessment of the 
metabolism of glioma relative to surrounding tissues. The high sensitivity of 18F-
DOPA imaging grants utility for a number of clinical applications.  
Methods 
A collection of published work about 18F-FDOPA PET was made and a critical 
review was discussed and written. 
Results 
A number of research papers have been published demonstrating that in 
conjunction with MRI, 18F-FDOPA PET provides greater sensitivity and specificity than 
these modalities in detection, grading, prognosis and validation of treatment success 
in both primary and recurrent gliomas. In further comparisons with 11C-MET, 18F-FLT, 
18F-FET and MRI, 18F-FDOPA has shown similar or better efficacy. Recently synthesis 
cassettes have become available, making 18F-FDOPA more accessible. 
Conclusions 
According to the available data, 18F-FDOPA PET is a viable radiotracer for 
imaging and treatment planning of gliomas. 
Advances in knowledge and implication for patient care 
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18F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis 
and treatment planning of gliomas cases, improving on that of MRI and 18F-FDG PET. 
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Introduction 
The potential of L-3,4-Dihydroxy-6-[18F]fluorophenylalanine (18F-FDOPA) as a 
tool for managing glioma was first identified by Heiss et al. in 1996 [14], following a 
long history of use in Parkinson’s Disease. In the light of recent improvements in 
tracer synthesis[1], and the likelihood of its increasingly widespread availability, a 
review of 18F-FDOPA is necessary. This is also timely, as despite continuing advances 
in treatment regimes, the prognosis of glioblastoma multiforme (WHO Grade IV 
gliomas; GBM) remains poor [2]. While the median survival rate now exceeds 12 
months, few patients live longer than two years [3-5]. 
While there is evidence that 18F-FDOPA can provide additional information in 
detecting gliomas and planning treatment, it is not widely used in either the research 
or clinical setting.  
One reason for this is the complex synthesis process involved. An automated 
electrophilic approach is available for radiotracer synthesis [6, 7], however 
difficulties with handling 18F in gaseous form as well as a low radiotracer production 
yield [8, 9]means a two-step electrophillic cpproach remains the most common 
method for synthesis[10, 11]. While these limitations may lessen the interest in 
synthesizing this radiotracer, recent developments have seen the introduction of 
nucleophilic approaches [12, 13], which produce 18F in liquid form. Given the 
complexity of electrophilic 18F-FDOPA synthesis and the proven track record for 11C-
MET to provide sensitive and specific measurements of glioma volumes, research 
facilities may opt to investigate cases using 11C-MET only. However the short half-life 
of 11-C means it generally needs to be produced on site. Despite this, the recent 
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availability of single-use synthesis cassettes for 18F-FDOPA could make its use 
feasible in more centres.  
Imaging is critical to the management of glioma for a number of reasons. 
Lower grade gliomas, while less aggressive, also have a poor prognosis with survival 
rates of between 2-5 years [14]. A significant factor in the management of low-grade 
tumours is the difficulty in predicting their transformation to a higher grade. A 
recent study showed that transformation of gliomas from low-grade to high-grade 
after recurrence can occur in 45-74% of cases, depending on the tumour subtype 
[15]. Recurrence is also of concern, as incidences subsequent to apparently complete 
regression can occur due to small colonies of residual cells that are capable of 
causing reemergence [16]. Recurrent lesions can result in extensive, ipsilateral or 
contralateral spread with severe symptoms and poor prognosis [17] and are often 
more aggressive than the initial primary lesion at the time of staging.  
The biology of recurrent tumour can differ from de-novo glioma due to the 
selective effect that treatment imposes on the disease, resulting in a phenotypic 
shift to more aggressive infiltration [18]. Treatment also affects surrounding healthy 
tissue by ameliorating the some of the symptoms caused by bulk effects, but also by 
having an inflammatory and necrotic effect [19]. Combined with the differences in 
management, these factors alter the task of assessing the tumour whether for the 
purposes of characterising treatment response, planning or prognosis. For instance, 
in recurrent tumour, pseudo progression must be distinguished from active tumour 
[20], and assessing the response of the tumour can be problematic where regions of 
recurrence surround a large cavity [21]. In contrast for low grade gliomas the 
radiological findings form a minority of the score obtained during assessment [22], 
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or if planning the resection of high grade tumours using PET the margins of 
identifiably active tumour can be more critical than say overall dimension [23]. 
Positron emission tomography (PET) imaging utilizing metabolic radiotracers 
such as [11C]methionine (11C-MET), 18F-Flurodeoxyglucose (18F-FDG) and 18F-
Fluromisonidazole (18F-FMISO) have been introduced into the pre-clinical, and to a 
lesser extent, the clinical setting. PET imaging has been shown to improve 
delineation of tumour volumes, as well as assist in grading of lesions and providing a 
prognosis, complementing information obtained through other modalities such as 
MRI [24-28]. An advantage of PET is that it directly examines an aspect of cellular 
metabolism that may be selected beforehand, while MRI is limited to identifying the 
physical effects of the tumour such as blood brain barrier breakdown or oedema. 
While such physical effects are useful they can be a less direct approach for inferring 
the location and progression of the tumour. 
18F-FDOPA is transported across the BBB by a number of amino acid 
transporters, which have been shown to be overexpressed in glioma [29] relative to 
background (healthy) tissue. In non-striatal tissue, 18F-FDOPA is converted into either 
18F-Flourodopamine by dopa carboxylase or the metabolite 3-O-methyl-6-fluoro-L-
DOPA (3-OMFD) by catechol-O-methyl transferase. The kinetics of 18F-FDOPA 
metabolism are similar to healthy tissue (see Fig. 4 in [30]), so it is likely the 
enhanced avidity  of tumours arises primarily from the increase uptake (K1) of 
the tracer.  
The PET radiotracer, 6-[18F]fluoro-dihydroxy-l-phenylalanine (18F-FDOPA) was 
first synthesised in the 1980’s for the purpose of examining Parkinson’s disease [31]. 
In 1996, a case study by Heiss et al [32] illustrated 18F-FDOPA as a potential 
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diagnostic tool for glioma. Further multi-modal studies investigating the lesion were 
suggestive of a low-grade glioma, with high 11C-MET uptake displayed within the 
same area. This unexpected, yet important finding was the first to describe the 
possibility that 18F-FDOPA may provide complimentary information to other amino 
acid PET tracers, such as 11C-MET and 18F-tyrosine, in the assessment of gliomas.  
The finding by Heiss et al  sparked a great interest in 18F-FDOPA. The 
literature suggests that this tracer may provide complimentary information to other 
diagnostic imaging. This paper provides an overview of the growing body of research 
focusing on the clinical applications of 18F-FDOPA PET imaging for the management 
of glioma. In the light of recent improvements in tracer synthesis[1], the current 
literature supports the argument for the wider scale adoption of 18F-FDOPA PET in 
clinical practice and for research purposes.  
A comparison of 18F-FDOPA PET with other modalities 
Complimenting MRI with 18F-FDOPA PET 
Contrast Enhanced MRI is used extensively in the diagnosis and management 
of primary and recurrent glioma. The contrast enhancing regions of MRI reveal 
regions where the blood brain barrier (BBB) is disrupted. However, the regions of 
infiltrating tumour are known to extend well beyond the margins of BBB disruption 
[33]. Although oedema is visible on a number of MRI sequences by the variations in 
intensity that it induces, this does not directly identify regions of active tumour [33]. 
There is growing evidence that information gained from other modalities may 
compliment that obtainable from MRI. This is especially true in low-grade and non-
enhancing glioma, where blood brain barrier (BBB) breakdown does not necessarily 
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occur. An advantage of amino acid radiotracers such as 18F-FDOPA is that they do not 
require a perturbed BBB, as transport of the tracer across the BBB is facilitated by 
amino acid transporters. Moreover, PET tracers allow particular aspects of cellular 
activity to be imaged more directly, as opposed to relying on the physical changes 
tumour activity induces. There is also a concern in recurrent glioma, where MRI 
alone cannot always discriminate enhancing tumour from treatment-induced 
parenchymal injury, so called post-treatment radiation effect [34, 35]. Post-
treatment radiation effects include pseudoprogression and radiation necrosis, 
believed to cause false declaration of treatment failure in up to 50% of cases [36-39]. 
Although the ability of MRI to distinguish between tumour and other tissue biology 
has been of significant interest[40-42], PET imaging may provide clinically relevant 
metabolic information that is not otherwise obtainable. For example, 18F-FDOPA and 
MR images of a glioma patient are shown in Figure 1. Although the tumour volume 
corresponds closely to that of the MRI, the high 18F-FDOPA uptake region extends 
beyond the contrast enhanced MRI region, potentially supplying a better estimate of 
the extent of tumour infiltration.  
In a study into 18F-FDOPA PET/MRI in primary and recurrent glioma, Ledezma 
et al [43] illustrated that the combination of 18F-FDOPA PET and MRI was accurate at 
detecting lesions. An interesting finding in this study was that 18F-FDOPA was unable 
to detect the glioma volume in four cases, whereas MRI was. The authors provide an 
explanation for one of these cases: following the scan the tumour shrank, possibly 
indicating that although tumour still remained, metabolic activity had been 
temporarily halted by treatment. Although MRI and 18F-FDOPA PET information was 
complementary, 18F-FDOPA proved to be a more sensitive modality by itself than 
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MRI, even with the false negative cases. A similar finding was made by Karunanithi et 
al [44] in a study comparing the diagnostic accuracy of contrast-enhanced MRI and 
18F-FDOPA in recurrent cases of glioma. 18F-FDOPA PET detection was correct in 34 
patients, with one false positive. MRI findings on the other hand, were only accurate 
in 28 patients, with false positives in five and false negatives in two. For the false 
positive case of 18F-FDOPA, the authors suggest that tracer uptake could be due to 
the high levels of amino acid transport into microphages that are activated after 
surgery, or leakage of 18F-FDOPA due to BBB breakdown caused by treatment. In a 
study by Kosztyla [45], locations of tumour recurrence were compared to the gross 
tumour volume (GTV) delineated on pre-treatment 18F-FDOPA and MRI images. 
Firstly, this study showed that inter-observer agreement between 18F-FDOPA PET 
and MRI delineations were not significantly different, although 18F-FDOPA GTVs were 
larger than that of MRI. Secondly, sites of tumour recurrence existed outside both 
MRI and 18F-FDOPA PET GTVs in all but one case. These results suggest that, 
although 18F-FDOPA PET may provide additional anatomically focal information 
compared to MRI, it does not imply an improvement in treatment would occur if 18F-
FDOPA PET alone is used for radiation therapy planning, as sites of future recurrence 
may exist outside the dose map.  
Hence, while MRI is currently implemented in the diagnosis and treatment of 
glioma, these studies support the potential of 18F-FDOPA as a modality that is 
complementary to MRI. Specifically, 18F-FDOPA could have utility where MRI findings 
are negative in primary/recurrent tumours or inconclusive in recurrent tumours.  
The use of 18F-FDOPA to complement MRI is made more feasible with the 
recent introduction of PET/MR imaging, where both PET and MR images are 
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acquired simultaneously, providing spatially and temporally registered images. 
PET/MRI has shown potential in both the clinical and pre-clinical setting for 
investigating areas of glioma treatment such as new drug development[46]. 
<<Location of Figure 1 >> 
Comparison with the PET tracers 11C-MET, 18F-FDG and 18F-FLT  
Primary glioma 
While the modality most widely used in treatment of gliomas is MRI, positron 
emission tomography (PET) is becoming more common, with the introduction of 
new radiotracers to compliment information gained from MRI. In the clinical 
environment, the most widely used radiotracer for imaging glioma is 18F-
Fluorodeoxyglucose (18F-FDG) and its use in glioma cases was the first oncological 
application of PET [47-50]. However, some studies have highlighted the diagnostic 
limitations of this tracer [51, 52]. Specifically, the high metbolic rate of normal brain 
tissue results in a high background uptake of the tracer. This increase in background 
activity limits the contrast between normal brain tissue and lesions, making it 
difficult to distinguish between normal tissue and possible lesions. This is of special 
concern in low-grade gliomas, where glucose metabolism has been shown to be 
similar to that of normal tissue [53, 54]. In addition, inflammatory lesions such as 
those from infection also have an elevated glucose metabolism, leading to false 
positives and incorrect diagnosis [55]. To overcome these limitations, studies have 
been performed to investigate 18F-FDOPA as a potential alternative to 18F-FDG in 
primary and recurrent gliomas.  
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Chen et al [53] illustrated the potential for 18F-FDOPA to effectively image 
primary gliomas as part of a wider study that also included clinically stable and 
recurrent patients. 18F-FDOPA was significantly more specific and sensitive than 18F-
FDG in primary lesions, demonstrating the diagnostic utility of this tracer. In a similar 
study, Tripathi et al [54] investigated amino acid metabolism, glucose metabolism 
and proliferation using 18F-FDOPA, 18F-FDG and 18F-FLT, respectively. Although this 
cohort contained only three patients with primary glioma, 18F-FDOPA uptake was 
positive in all cases, whereas 18F-FLT and 18F-FDG uptake was only observed in one. 
Jora et al [56] and Jacob et al [57] both performed comparative investigations into 
the uptake of 18F-FDOPA, 13N-Ammonia, 18F-FDG and MRI in low and high-grade 
primary and recurrent gliomas. Both studies reported that 18F-FDOPA was 
significantly more reliable in the detection of primary gliomas than 13N-Ammonia or 
18F-FDG.  
The above studies demonstrate 18F-FDOPA’s utility to detect primary low and 
high-grade gliomas and as a potentially superior alternative to 18F-FDG and 18F-FLT.  
In addition to 18F-FDOPA, other amino acid radiotracers have been shown to 
detect glioma [58], including the 18F-FDOPA metabolite, 3-O-methyl-6-18F-fluoro-L-
dopa (OMFD) [59]. A frequently utilized tracer in this research field is 11C-MET, which 
has been investigated extensively [5, 60] and is known to be more effective than 11C-
glucose [61] and CT [62, 63]. However, 11C-MET has the drawback of a short half-life 
(20.4 minutes), limiting its availability to centers that are in close proximity to a 
cyclotron. The 110 minute half-life of 18F radiotracers make them viable in a wider 
variety of scenarios. Becherer et al [64] investigated this potential in 20 patients, 18 
of which were diagnosed with primary glioma. Results showed that the standard 
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uptake values (SUVs) of 18F-FDOPA and 11C-MET 20 minutes post injection showed a 
significant correlation (P<0.05) and visual inspection revealed almost identical 
patterns of spatial uptake. Since both tracers are taken up via amino acid channels, 
this study suggests that there is a significant potential for 18F-FDOPA imaging of 
gliomas where 11C-MET may be difficult to obtain due to its short half-life. 
Recurrent glioma 
While 18F-FDG is used extensively in the diagnosis and treatment of both 
primary and recurrent gliomas, it is also used in conjunction with MRI to detect 
recurrent disease, which is frequent in glioma. Detection of low-grade gliomas using 
18F-FDG has limitations due to both the low contrast ratio between tumour and 
normal tissues, and uptake in inflammatory lesions [53-55]. Not only is this an issue 
for low-grade recurrent gliomas [52], but studies suggest that this is also the case in 
high-grade recurrent gliomas [50, 65]. 
As with their findings for primary gliomas, Chen et al [53] and Tripathi et al 
[54] demonstrated that 18F-FDOPA also outperforms 18F-FDG in the detection of 
recurrence. In similar studies, Jacob et al [57] and Jora et al [56] showed that the 
performance of 18F-FDOPA was superior compared to that of 13N-Ammonia and 18F-
FDG. 
Karunanithi et al [66] investigated using 18F-FDOPA uptake to detect glioma 
recurrence. In a comparison to 18F-FDG, 18F-FDOPA gave better results. For 28 
patients, 21 with recurrent disease, 18F-FDOPA was able to detect all recurrences, 
with only one false positive occurrence, while 18F-FDG was only able to detect 10 of 
the 21 recurrences, with no false positives. Notably, the only recurrences detectable 
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by 18F-FDG were grade IV tumours (10 out of 11 recurrences), possibly due to the 
high glycolysis known to occur in this grade of glioma. 
PET kinetic compartment modeling can be used to analyse the temporal 
behavior of tracers in the body, and has been investigated previously in radiotracers 
such as 18F-FDOPA [30]. Kratochwil et al [67] also used a kinetic analysis to compare 
the uptake of 18F-FDOPA and 18F-FET in 16 high and low-grade recurrent gliomas. 
While results showed that 18F-FDOPA was able to detect all 16 lesions, 18F-FET only 
detected 15, failing to identify one grade II astrocytoma. This study suggests that 
both radiotracers used in conjunction with kinetic modeling have potential to assist 
in diagnosis of gliomas, though 18F-FDOPA may be more effective in tumours distant 
from the striatum. 
Comparison with SPECT imaging  
In addition to MR and PET imaging, SPECT has been investigated for glioma 
grading [68-70], predicting survival [71] and identifying recurrence [72-74]. In a study 
by Karunanithi et al [75], tumour recurrence was assessed by both 18F-FDOPA PET 
and 99mTc-GH SPECT/CT in 30 patients previously treated for histopathologically 
proven glioma. Of the 30 patients, 22 were positive for recurrence. 18F-FDOPA was 
able to correctly identify recurrence in all cases, with only a single false positive. In 
contrast, only 19 of the 22 tumours were identifiable using SPECT imaging, with an 
additional 3 false positives cases occurring. While 18F-FDOPA better detected glioma 
recurrence, the authors note that since SPECT imaging is a more economical 
modality, 99mTc-GH SPECT/CT could be a viable alternative for assessing glioma 
recurrences in cases where cost is of concern. 
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Applications of 18F-FDOPA 
Using 18F-FDOPA to predict survival 
In addition to 18F-FDOPA’s utility in detecting primary and recurrent tumours, 
the ability to predict survival would also be of substantial use. Currently, several 
factors, such as Karnovsky performance status (KPS), age, tumour size, extent of 
surgery and tumour grade and histology are used in predicting patient survival [76, 
77]. Previous studies have shown that 18F-FDG is also effective in predicting survival 
in primary and recurrent glioma patients [78, 79]. However, the low specificity of 18F-
FDG PET is a limitation. Karunanithi et al [80] investigated predictability of survival 
using 18F-FDOPA in 33 patients with suspected recurrence. To accomplish this, 
positive 18F-FDOPA uptake and 18F-FDOPA indices of SUVmax, tumour to normal tissue 
ratio (T/N), tumour to striata (T/S), tumour to white matter (T/W) and tumour to 
cerebellum (T/C) were calculated from 18F-FDOPA PET images. Tumour volume size 
was also calculated from MRI. Univariate analysis showed that several factors predict 
survival with significance, including: positive uptake (P=0.007), SUVmax (P=0.001), T/N 
(P=0.001), T/S (P=0.005), T/W (P=0.0004) and T/C (P=0.003). In multivariate analysis, 
only MRI tumour size (P=0.002) and T/N (P=0.005) were found to be independent 
predictors of survival. Receiver-operating characteristic ROC analysis was performed, 
with T/N greater than 1.51 and MRI tumour size greater than 2.5 cm indicative of a 
poorer predicted survival. This study suggests that 18F-FDOPA is predictive of patient 
survival in cases of recurrent glioma. Dowson et al [81] further illustrated the 
prognostic capability of 18F-FDOPA by showing that the uptake changes in the most 
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treatment resistant region of tumour post-treatment are predictive of patient 
survival.  
Using 18F-FDOPA to predict survival 
In addition to 18F-FDOPA’s utility in detecting primary and recurrent tumours, 
the ability to predict survival would also be of substantial use. Currently, several 
factors, such as Karnovsky performance status (KPS), age, tumour size, extent of 
surgery and tumour grade and histology are used in predicting patient survival [76, 
77]. Previous studies have shown that 18F-FDG is also effective in predicting survival 
in primary and recurrent glioma patients [78, 79]. However, the low specificity of 18F-
FDG PET is a limitation. Karunanithi et al [80] investigated predictability of survival 
using 18F-FDOPA in 33 patients with suspected recurrence. To accomplish this, 
positive 18F-FDOPA uptake and 18F-FDOPA indices of SUVmax, tumour to normal tissue 
ratio (T/N), tumour to striata (T/S), tumour to white matter (T/W) and tumour to 
cerebellum (T/C) were calculated from 18F-FDOPA PET images. Tumour volume size 
was also calculated from MRI. Univariate analysis showed that several factors predict 
survival with significance, including: positive uptake (P=0.007), SUVmax (P=0.001), T/N 
(P=0.001), T/S (P=0.005), T/W (P=0.0004) and T/C (P=0.003). In multivariate analysis, 
only MRI tumour size (P=0.002) and T/N (P=0.005) were found to be independent 
predictors of survival. Receiver-operating characteristic ROC analysis was performed, 
with T/N greater than 1.51 and MRI tumour size greater than 2.5 cm indicative of a 
poorer predicted survival. This study suggests that 18F-FDOPA is predictive of patient 
survival in cases of recurrent glioma. Dowson et al [81] further illustrated the 
prognostic capability of 18F-FDOPA by showing that the uptake changes in the most 
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treatment resistant region of tumour post-treatment are predictive of patient 
survival.  
Using 18F-FDOPA to grade gliomas 
Tumour grading using in vivo imaging such as 18F-FDOPA PET is also of 
significant interest. The current accepted method for tumour grading involves either 
surgical biopsy or resection (if possible), after which tumour vascularity is assessed 
pathologically [82]. However, there are significant limitations to performing biopsies 
alone. Firstly, biopsies are not always possible due to the tumour location or patient 
condition. Secondly, there is a possibility that the tumour is underestimated or 
misrepresented by the small sample of tissue acquired, as more aggressive cells may 
exist in other areas of the tumour volume. [83]. Finally, additional neurological 
damage and morbidity can occur due to the invasiveness of the procedure [84]. Both 
18F-FMISO [24, 25, 85]and 18F-FDG [65] have also been investigated for glioma 
grading.  
As part of their study, Chen et al [53] found no ability for 18F-FDOPA to be 
able to differentiate between high-grade and low-grade gliomas (P=0.40). Fueger et 
al [86] investigated the potential for 18F-FDOPA to predict glioma grade in 59 
patients with newly diagnosed glioma. 18F-FDOPA SUVmax corresponded significantly 
with glioma grade, with correlation values P=0.044, P=0.007 and P=0.010 
representing grade II vs. grade III, grade II vs. grade IV and grade III vs. grade IV, 
respectively. However, this correlation was significantly reduced in recurrent 
gliomas, with only grade II vs. grade III and grade II vs. grade IV reaching statistical 
significance. These results suggest that there is a potential for 18F-FDOPA to be used 
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in grading newly diagnosed gliomas. However, when considering recurrent gliomas 
this may not be possible. In agreement with Fueger et al, Pafundi et al [87] also 
found that 18F-FDOPA SUVmax strongly correlated with tumour grade in ten patients 
(P=0.0005), although they excluded oligodendrogliomas, due to an asymptomatic 
uptake observed within this tumour type. Nioche et al [88] also investigated 18F-
FDOPA for potential glioma grading using both static and dynamic PET acquisitions. 
Results from this study concurred with that of Fueger et al, with the authors able to 
discriminate between high and low grade primary gliomas using static 18F-FDOPA PET 
imaging. However, the authors also found that high-grade and low-grade gliomas 
could also be discriminated in recurrent gliomas. Results improved, although not 
significantly, when kinetic factors, extracted from dynamic imaging, were used 
instead of static imaging.  
Kratochwil et al [67] compared the uptake of 18F-FDOPA and 18F-FET in 16 
high and low-grade recurrent gliomas. 18F-FDOPA uptake peaked earlier than 18F-FET 
in both high and low-grade and also provided a much higher tumour-to-blood (T/B) 
ratio. 18F-FDOPA uptake peaked after 8 minutes in high grade and 10 minutes in low 
grade, while 18F-FET uptake peaked at 9 minutes and 40 minutes. The additional time 
between uptake peaks of high and low grade glioma in 18F-FET suggests that dynamic 
scanning may allow the discrimination between tumour grades. However, 18F-FDOPA 
lacks a significant temporal gap between high and low tumour grades, potentially 
ruling out its use for this purpose. 
From these studies, there appears to be some evidence that 18F-FDOPA can 
assist in tumour grading, though further research is needed before conclusions can 
be made.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Using 18F-FDOPA for neurosurgical and radiotherapy planning 
For planning of both resection and radiation therapy, MRI is widely accepted 
as the gold standard, with T1-contrast-enhanced (T1-CE) MRI and T2/FLAIR imaging 
sequences utilized. However, ongoing research has shown that MRI has limitations, 
due to lack of contrast enhancement in tumoural regions [89], high contrast 
enhancement in benign tumours and lesions [89] and a lack of discriminability 
between malignant tissue and oedema on T2/FLAIR imaging [90, 91]. The inclusion of 
an additional imaging modality to compliment information available from MRI has 
the potential to assist in neurosurgery and radiation therapy planning, improving 
patient outcomes. Pafundi et al [87] investigated this potential in ten patients with 
diagnosed primary or recurrent glioma. 18F-FDOPA and MR imaging was performed 
to identify areas of tracer uptake and contrast enhancement. Biopsies were 
performed for all patients in regions of both MRI and 18F-FDOPA concordance and 
discordance, resulting in a total of 23 tissue samples. Pathological results found 22 of 
the 23 samples were positive for malignancies. 13 of 16 high-grade biopsy specimens 
were obtained from regions of high 18F-FDOPA uptake, whereas only 6 of 16 of these 
regions showed enhancement of MRI. Three samples were obtained from areas 
where there was no high 18F-FDOPA uptake or contrast enhancement. Three of the 
six low-grade specimens were taken from areas of high 18F-FDOPA uptake, whereas 
contrast enhancement was negative in all six cases. These findings have two 
important implications. Firstly, 18F-FDOPA has the potential to identify areas of 
tumour infiltration that is not necessarily evident on MRI, necessitating an additional 
modality to compliment MRI findings. Secondly, infiltrative tumour tissue can also 
exist outside regions of both 18F-FDOPA uptake and MRI contrast enhancement.  
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For the treatment of high-grade gliomas with radiotherapy, the margin added 
to the gross tumour volume, defined on the contrast enhancing MRI, is 1-2cm to 
account both for occult infiltration and movement between fractions. In the study by 
Pafundi et al [76], two patients exhibited high tracer uptake outside the planned 
tumour volume, suggesting that a 1-2cm expansion does not fully account for 
infiltration in all cases. 
Using 18F-FDOPA to assess treatment response 
PET imaging is also being investigated as a method for identifying tumour 
response to new treatments. It is well known that vascular endothelial growth 
factors (VEGF) play a crucial role in modulating angiogenesis and tumorigenesis, with 
hypoxia being able to stimulate VEGF secretion through activation of hypoxia-
inducible transcription factors (HIFs) [92]. Since the prognosis of glioma is so poor, 
anti-angiogenic drugs that target VEGF have been suggested and introduced into the 
treatment regime [2, 93-100]. Bevacizumab is one such anti-angiogenic treatment, 
designed to inhibit vascular growth following radiotherapy. Although this treatment 
has already been introduced into the clinical environment, evaluation of its 
effectiveness is still of significance.  
In a study by Harris et al [101], bevacizumab treatment was evaluated in 24 
patients with recurrent gliomas using serially acquired 18F-FDOPA PET, 18F-FLT PET 
and MR imaging. Using voxel-wise changes between acquisitions, parametric 
response maps (PRMs) were generated for both 18F-FDOPA and 18F-FLT PET tracers 
as well as MRI. Scans were acquired before and twice after administration of 
bevacizumab treatment. Results from the study showed that an increase in tracer 
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uptake volume in PRMs was associated with a shortened progression free survival. 
However, only a weak correlation was found between PRM and overall survival, 
suggesting the need for further research.  
18F-FDOPA imaging could influence treatment pathways 
While it is important to assess the ability for new imaging techniques to assist 
in patient diagnosis and treatment, advances in research are futile if physicians do 
not adopt them. In a study by Walter et al [102], the frequency with which 18F-
FDOPA altered the treatment regime was assessed. For 58 patients, pre-PET, early 
post-PET and late post-PET surveys were conducted. Survey statistics showed that a 
considerable percentage of treatment paths were altered when 18F-FDOPA imaging 
was considered. It was shown that after considering 18F-FDOPA PET imaging, clinical 
suspicion of tumour recurrence decreased in 17%, remained the same in 50% and 
increase in 33% of cases. In addition, survey results showed that 18F-FDOPA imaging 
altered the intended treatment path of 41% of patients, i.e., treatment approaches 
altered from “wait and see” to invasive treatments and vice-versa. Late post-PET 
surveys showed that these changes to the intended treatment path were carried out 
in 75% of cases. This illustrated that 18F-FDOPA has the potential to have a 
substantial effect on treatment course, with implementation within the clinical 
environment having the potential to assist in patient treatment regimes.   
18F-FDOPA as a tool for cross-validation with new modalities 
Recently, 18F-FDOPA PET imaging has been used to evaluate and validate new 
techniques and research. Numerous studies have investigated the potential for MR 
imaging indices, such as apparent diffusion coefficient (ADC), for pre-operative 
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tumour grading and treatment planning [103-107]. However, findings from these 
studies have been mixed. Rose et al [108] investigated the correlation between 18F-
FDOPA standard uptake value ratio (SUVR) and minimum ADC volumes to attempt to 
understand the relationship. Results from the study showed that there was little 
relationship between the two modalities, supporting the idea that areas of low ADC 
may in fact be related to compression from oedema or even ischemia. 
Bell et al [109] used 18F-FDOPA PET imaging to validate a method for 
generating a probability map and describing tumour cell infiltration, using MRI 
indices and whole brain tractography. They were able to show that identification of 
tumour boundaries was more accurate when delineations took into account 
progression of infiltrative tumour cells along white matter tracts. 
18F-FDOPA in detection of brain metastases 
Additionally, two studies have been performed to investigate 18F-FDOPA PET imaging 
for discrimination of brain metastasis from post-treatment effects. Using 18F-FDOPA 
PET, Lizarraga et al [110] studied 32 patients suspected of metastic progression to 
investigate whether 18F-FDOPA PET could distinguish between metastases and 
radiation injury. Using visual interpretation, a sensitivity and specificity of 81.3% and 
84.3% respectively was achieved across the cohort. Similarly, Cicone et al [111] 
investigated 18F-FDOPA PET for differentiating radiation necrosis from tumour 
progression in 42 patients with suspected brain metastic progression. A semi 
quantitative PET measure of maximum lesion to maximum background uptake ratio 
was found to be the best discriminator, with a ratio threshold of 1.59 yielding a 
sensitivity and specificity of 90% and 92.3% respectively.  
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These two studies suggest that 18F-FDOPA may also be used to discriminate metastic 
tumour progression from post-treatment injuries such as radiation necrosis in 
previously treated patients. 
Limitations of 18F-FDOPA 
In addition to the limitations imposed by tracer synthesis, the effect of 
treatment procedures on 18F-FDOPA uptake has also been investigated. As part of 
their study, Ledezma et al [43] highlighted mild 18F-FDOPA activity along the tumour 
resection boundary in several cases studied. More recently, Chiaravalloti et al [112] 
found a relationship between 18F-FDOPA uptake in patients with suspected tumour 
recurrence and the delay in PET imaging post radiotherapy. Results showed that 
uptake decreased with increasing delay over months, suggesting that a high uptake 
soon after radiotherapy may be treatment related, and as such, care should be taken 
when assessing patients with suspected tumour recurrence using 18F-FDOPA PET.  
Finally, 18F-FDOPA is an amino acid tracer that targets dopamine receptors in 
the brain, resulting in high uptake within the striatum. As such, care should be taken 
when assessing tumours in near proximity to the striatum, as high uptake in this area 
may blur the understanding of the tumour boundary. Distinguishing tumour from 
healthy tissue in these areas probably entails performing a kinetic analysis of the 
data, and even then partial volume effects will result in some residual imprecision in 
the definition of the boundary. 
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Conclusion 
The discovery that 18F-FDOPA PET can localize gliomas instigated a number of 
recent research studies. The literature has demonstrated 18F-FDOPA PET’s efficacy 
for diagnosis, prognosis and treatment evaluation of patients with both primary and 
recurrent low and high-grade glioma, especially when complimenting MRI. As such, 
18F-FDOPA has shown its potential to alter treatment regimes in a large fraction of 
glioma cases. Despite its potential, 18F-FDOPA is not widely used in either the 
research or clinical setting.  
Currently, the complex production of 18F-FDOPA by means of electrophilic 
synthesis requires significant equipment and knowledge. Recently, single-use 
cassettes for the nucleophilic synthesis 18F-FDOPA have become available. The more 
practical synthesis of 18F-FDOPA, could potentially enable its more widespread use, 
especially given the more limited utility of 18F-FDG and the requirement of an onsite 
cyclotron for 11C-MET. 
Limitations of 18F-FDOPA also include its high uptake by the basal ganglia. 
While this is a key feature in its use within the management of neuro-degenerate 
diseases, the diagnostic ability of the tracer is limited for tumours adjacent to this 
region. Hence it is likely to remain complimentary to MRI, the standard modality for 
imaging glioma patients. 
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Figure 1 – a) Contrast enhanced MRI and b)18F-FDOPA imaging of a primary high-grade glioma (grade 
IV – GBM). 
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Table 1 - Summary of clinical 18F-FDOPA PET studies. (HG – High grade; LG – Low grade; PBT – 
Primary brain tumour; DF – Disease free; NG – Non-glioma; PTC – Posttreatment changes; NA – Not 
applicable; PFS- Progression free survival; OS – Overall survival; TP – True Positive; FP – False Positive) 
Reference No. patients tumours quantity and 
type 
Study Results 
[22] 1 1 Low grade Case study into possible 
neuro-degenerative 
disorder. 
Unintentional discovery of low-grade glioma. 
[53] 20 18 Primary 
2 Disease free 
Investigate the 
relationship between 
11
C-MET and 
18
F-FDOPA 
uptake. 
Uptakes were very similar. 
11
C-MET SUVR: 
2.04±0.53; 
18
F-FDOPA SUVR: 2.05±0.91. Visual 
uptake was also very similar. 
[42] 81 18 Grade II 
13 Grade III 
35 Grade IV 
11 PTC 
4 Remission 
Compared 
18
F-FDG and 
18
F-FDOPA uptake in 
primary and recurrent 
gliomas. 
18
F-FDOPA sensitivity: 96%; 
18
F-FDOPA 
specificity: 43%; 
18
F-FDG sensitivity: 61%; 
18
F-
FDG specificity: 43%. 
18
F-FDOPA could not discriminate between 
low and high grade glioma. 
[43] 15 3 Grade I 
9 Grade II 
3 In Remission 
Compared 
18
F-FLT, 
18
F-
FDG and 
18
F-FDOPA in 
low-grade gliomas. 
18
F-FDOPA – TP: 12 FP: 0  
18
F-FDG – TP: 7 FP: 0  
18
F-FDOPA – TP: 4 FP: 0 
[45] 23 6 Primary 
10 Recurrent 
7 Disease free 
Pilot study into the 
comparison of 
18
F-
FDOPA, 
18
F-FDG, 
13
N-
Ammonia and MRI. 
Sensitivity (%): 
18
F-FDG - 44, 
13
N-Ammonia – 
25 
18
F-FDOPA – 100 MRI – 81  
Specificity (%):
 18
F-FDG - 86, 
13
N-Ammonia – 
86 
18
F-FDOPA – 71 MRI – 43 
[33] 91 33 Grade II 
24 Grade III 
34 Grade IV 
Investigated 
18
F-FDOPA 
PET/MRI fusion for 
glioma detection. 
Group I – had histology 
to confirm 
Group II – Confirmation 
from serial MRI 
18
F-FDOPA PET and MRI individually provided 
vital information for glioma detection. 
Group I – 
18
F-FDOPA sensitivity: 95.2%, MRI: 
90.5% 
Group II – MRI/PET concordance: 90.1% 
[65] 30 22 Recurrent Compared 
18
F-FDOPA 
18
F-FDOPA outperformed 
99m
TC-GH SPECT in 
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8 Remission and 
99m
TC-GH SPECT for 
recurrence of glioma. 
detection of recurrent gliomas. 
18
F-FDOPA – TP: 22 TN: 7 
99m
TC-GH – TP: 19 TN: 5 
[70] 33 25 Recurrent 
8 Remission 
Assessed potential for 
18
F-FDOPA to predict 
survival in recurrent 
gliomas. 
18
F-FDOPA tumour-to-normal (T/N) ration and 
MRI tumour size was significant in 
multivariate analysis of survival.  
T/N > 1.51 and MRI tumour size > 2.5 was 
indicative of poor prognosis. 
[34] 35 26 Recurrent 
9 Remission 
Compared MRI and 
18
F-
FDOPA uptake in 
patients with suspected 
recurrent glioma. 
18
F-FDOPA was more specific than MRI in 
tumour detection. 
18
F-FDOPA sensitivity, specificity, accuracy: 
100%, 89%, 97% 
MRI sensitivity, specificity, accuracy: 92%, 
44%, 80%
 
[55] 28 21 Recurrent 
7 Remission 
Compared 
18
F-FDG with 
18
F-FDOPA in detection 
of recurrent gliomas. 
18
F-FDOPA outperformed 
18
F-FDG in detection 
and diagnosis of recurrent glioma. 
18
F-FDOPA sensitivity, specificity, accuracy: 
100%, 86%, 96% 
18
F-FDG sensitivity, specificity, accuracy: 47%, 
100%, 61%
 
[71] 9 9 Grade IV Investigated 
18
F-FDOPA 
uptake for predicting 
survival. 
Treatment resistant clusters of cells were 
predictive of patient survival. A 1% reduction 
of uptake in the most intense cluster reduce 
the hazard to the patient by 10%.
 
[76] 59 13 Grade II 
19 Grade III 
27 Grade IV 
Investigated potential 
of 
18
F-FDOPA to grade 
gliomas. 
Tumour grades could be discriminated in 
primary, but not recurrent gliomas using 
18
F-
FDOPA SUVmax 
Primary SUVmax: LG - 4.22 ± 1.30, HG - 2.34 ± 
1.35, P=0.005 
Recurrent SUVmax: LG - 3.36 ± 1.26 HG - 2.67 ± 
1.18, P=0.22 
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[78] 33 15 Grade II 
10 Grade III 
8 Grade IV 
Investigated potential 
of 
18
F-FDOPA to grade 
gliomas in static and 
dynamic scans. 
Static scan: 5 minute scan 38 minutes post 
injection could discriminate HG and LG 
primary glioma with a sensitivity and 
specificity of 70% and 90%, respectively, with 
a threshold of SUVmean = 2.5. Sensitivity and 
specificity of 100% and 80%, respectively for 
recurrent gliomas when threshold of 1.8 was 
used. 
Dynamic imaging did not significantly improve 
ability to discriminate between HG and LG 
tumours.  
[91] 24 24 Recurrent Evaluated potential for 
18
F-FLT and 
18
F-FDOPA 
serial PET, 1 pre- and 2 
post-treatment, to 
predict response to 
treatment. 
Decrease in 
18
F–FDOPA uptake predicted 
longer PFS and OS. An increase in 
18
F-FDOPA 
predicted shorter PFS and OS. Volume fraction 
of increased 
18
F-FDOPA between the 2 post 
treatment time points predicted long and 
short term PFS and OS P < 0.05. 
18
F-FLT uptake 
did not stratify OS. 
[98] 15 Grade IV Used 
18
F-FDOPA to 
investigate the role of 
ADC in clinical 
evaluation of glioma. 
18
F-FDOPA uptake and minimum ADC showed 
minimal overlap, suggesting minimum ADC 
could be due to oedema and ischemia, not 
tumour proliferation. 
[99] 143 Grade IV Used 
18
F-FDOPA to 
validate a framework 
for identifying tumour 
infiltration in high-
grade gliomas. 
Incorporating white matter fiber tracks, 
delineation of tumour boundaries was 
improved in all cases. 
[92] 58 NA Investigated how 
18
F-
FDOPA influenced 
decisions on treatment 
in the clinical setting. 
18
F-FDOPA was influential in the diagnosis of 
glioma, and altered treatment in a number of 
cases. Suspicion for recurrent increased in 
33%, remain the same in 50% and decrease in 
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17%. 
18
F-FDOPA altered treatment plan in 41% 
and this change was followed through in 75%. 
[57]  18 8 Low grade 
8 High grade 
Compared uptake and 
diagnostic value of 
18
F-
FDOPA and 
18
F-FET.
 
Uptake of 
18
F-FDOPA was higher that 
18
F-FET 
in tumours. 
18
F-FDOPA able to detect all 
recurrent lesions, whereas 
18
F-FET detected all 
but one. 
18
F-FET can provide information on 
tumour grade using dynamic scanning 
[77] 10 8 High grade 
2 Low grade 
Histopathologically 
compared 
18
F-FDOPA 
uptake and MRI to 
evaluate the use of 
18
F-
FDOPA for radiation 
therapy planning 
Biopsy results showed that 
18
F-FDOPA uptake 
in areas lacking MRI contrast enhancement 
corresponded to malignant tissue. 
18
F-FDOPA 
was more sensitive than MRI for identifying 
tumour boundaries. 
[56] 37 10 Grade IV 
10 Grade III 
13 Grade II 
4 NG 
Investigated kinetic 
modeling of tissue 
types in dynamic 
18
F-
FDOPA imaging of 
glioma. 
A 2-compatment model was able to describe 
tumour and cerebellum tissues. A 3-
compartment model, with specific corrections, 
was able to describe tumour and striata. High-
grade gliomas had a significantly higher influx 
rate, equilibrium distribution volume and 
transport rate than lower-grade tumours. 
 
 
